Research Updates

Back to feed
Clinical trials
Registered study

High importance

Oct 7, 2026

Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)

View original source

Why it matters

This research is critical as it explores a novel treatment avenue for HHT, a condition affecting vascular health, potentially improving patient quality of life and reducing healthcare burdens associated with frequent blood transfusions.

Objective

To assess the safety and tolerability of TX002100 in participants with hereditary hemorrhagic telangiectasia (HHT), as well as its effects on reducing the need for blood or iron treatments and improving blood counts.

Results

Results are expected to clarify the safety profile of TX002100 and its potential efficacy in decreasing dependency on blood products, thus providing preliminary data on its impact on HHT-related anemia.

Methods

The study employs a Phase 1b trial design involving participants diagnosed with HHT, monitoring safety parameters and evaluating clinical outcomes related to blood treatment needs and hemoglobin levels.

Limitations

As a Phase 1b study, the sample size may be limited, and results may not be generalizable to all HHT patients or may require further validation through larger studies.

For your doctor:

ClinicalTrials.gov: NCT07863609

Abstract

The primary purpose of this study is to assess the safety and tolerability of TX002100 in participants with hereditary hemorrhagic telangiectasia (HHT). The study will also look at whether TX002100 reduces the need for blood or iron treatments, and whether it improves blood counts, such as hemoglobin levels.

Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT) · Research Updates